• Research
  • Lab Members
  • Publications
  • Patents
  • Lab News
  • Resources
  • Join the Lab
  • Contact Us
  • Fredhutch.org
  • About Us
  • Ways To Give
Fred Hutch Logo

Nabet Lab

Nabet Lab

Fred Hutch Logo
  • Research
  • Lab Members
  • Publications
  • Patents
  • Lab News
  • Resources
  • Join the Lab
  • Contact Us
  • Nabet Lab
  • Patents

Patents

2023 | 2020 |  2018 | 2017


2023

Inhibitors of the peptidyl-prolyl cis/trans isomerase (PIN1), combinations and uses thereof. WO/2023/278603. January 5 2023.

2020

Small-molecule Focal Adhesion Kinase (FAK) inhibitors. WO/2020/231726. November 19 2020.

Small molecule degraders of FKBP12 via recruitment of von Hippel-Lindau E3 ubiquitin ligase (VHL) E3 ubiquitin ligase, and uses in dTAG systems. WO/2020/146250. July 16 2020.

Degradation of FAK or FAK and ALK by conjugation of FAK and ALK inhibitiors with E3 ligase ligands and methods of use. WO/2020/069117. April 2 2020.

2018

Regulating chimeric antigen receptors. WO/2018/148440. August 16 2018.

Tunable endogenous protein degradation with heterobifunctional small molecules. WO/2018/148443. August 16 2018.

2017

Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses. WO/2017/024318. February 9 2017.

Tunable endogenous protein degradation. WO/2017/024319. February 9 2017.

Fred Hutch Logo
Fundraise
Donate
Facebook Twitter YouTube Pinterest Instagram LinkedIn
Quick Links
  • Find a Job at Fred Hutch
  • Subscribe to Hutch News
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center | 1100 Fairview Ave. N., Seattle, WA 98109
© 2025 Fred Hutchinson Cancer Center, a 501(c)(3) nonprofit organization.